Nuada Pharmaceuticals

Nuada Pharmaceuticals is a private specialty pharmaceutical company based in Dublin, Ireland, led by a veteran management team with extensive experience in the global pharmaceutical industry. The company is best known for its role as the founding entity of Adapt Pharma, which developed and commercialized NARCAN (naloxone HCl) Nasal Spray, the first FDA-approved needle-free treatment for opioid overdose. Following the acquisition of Adapt Pharma by Emergent BioSolutions in 2018 for up to $735 million, the Nuada team has continued to focus on the development of innovative medicines in niche therapeutic areas. The company utilizes a virtual business model, leveraging strategic partnerships to advance clinical-stage assets through regulatory approval and commercialization. Nuada's leadership includes former executives from Elan and Azur Pharma, bringing a strong track record of value creation in the specialty pharma sector.